# US 2016/0355822 A1 · Inhibitory oligonucleotides and their use in therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355822 A1
- Document ID: US20160355822A1
- Status: Published application
- Kind: A1
- Application number: 15/244,879
- Filed: 2016-08-23
- Published: 2016-12-08
- Earliest claimed: 2013-01-14
- Applicants: Sarepta Therapeutics, Inc.
- Inventors: Eugen Uhlmann; Marion Jurk; Thomas Lehmann
- Web page: https://patentgrep.com/patent/US20160355822A1

## CPC

- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/315: Phosphorothioates
- C12N 2310/33: of the base
- C12N 2310/334: Modified C
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/336: Modified G
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/345: having at least two different backbone modifications
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/53: reducing unwanted side-effects
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Inhibitory oligonucleotide having the general formula: X1CCN1N2N3X2N4N5GGGN6X3N7 (I) are disclosed which can be used in pharmaceutical compositions, whereby in formula (I) C is cytidine or a derivative thereof, whereby the cytidine derivative is selected from the group consisting of 5-methylcytidine, a cytidine-like nucleotide having a chemical modification involving the cytosine base, cytidine nucleoside sugar, or both the cytosine base and the cytidine nucleoside sugar, 2′-O-methylcytidine, 5-bromocytidine, 5-hydroxycytidine, ribocytidine and cytosine-β-D-arabinofuranoside, G is guanosine or a derivative thereof, whereby the guanosine derivative is selected from the group consisting of 7-deazaguanosine, a guanosine-like nucleotide having a chemical modification involving the guanine base, the guanosine nucleoside sugar or both the guanine base and the guanosine nucleoside sugar, X1 and X3 is any nucleotide sequence with 0 to 12 bases and each nucleotide is independent of any other, X2 is any nucleotide sequence having 0 to 3 nucleotides, N1, N2 and N3 are each independently any nucleotide, N4 and N7 is a pyrimidine or a modified pyrimidine, N5 is a purin or a modified purin, N6 is a modified pyrimidine, A or a modified purin, wherein at least two of the nucleotides N4, N5, N6 or N7 are modified purins or modified pyrimidines.

## Claims

### Claim 1

An inhibitory oligonucleotide having the general formula (I):
X1CCN1N2N3X2N4N5GGGN6X3N7 (I)
wherein:
C is cytidine or a derivative thereof, whereby the cytidine derivative is selected from the group consisting of 5-methylcytidine; a cytidine-like nucleotide having a chemical modification involving the cytosine base, cytidine nucleoside sugar, or both the cytosine base and the cytidine nucleoside sugar; 2′-O-methylcytidine; 5-bromocytidine; 5-hydroxycytidine; ribocytidine; and cytosine-β-D-arabinofuranoside,
G is guanosine or a derivative thereof, whereby the guanosine derivative is selected from the group consisting of 7-deazaguanosine; a guanosine-like nucleotide having a chemical modification involving the guanine base, the guanosine nucleoside sugar or both the guanine base; and the guanosine nucleoside sugar,
X1 and X3 are each independently any nucleotide sequence with 0 to 12 bases,
X2 is any nucleotide sequence having 0 to 3 nucleotides,
N1, N2 and N3 are each independently any nucleotide,
N4 and N7 is a pyrimidine or a modified pyrimidine,
N5 is a purine or a modified purine, and
N6 is a modified pyrimidine, A or a modified purine,
wherein at least two of the nucleotides N4, N5, N6 or N7 are modified purines or modified pyrimidines.

### Claim 2 (depends on 1)

The inhibitory oligonucleotide according to claim 1 having the general formula (I) set forth therein, wherein:
C is cytidine or a derivative thereof as defined in claim 1,
G is guanosine or a derivative thereof as defined in claim 1,
X1 and X3 are each independently any nucleotide sequence with 0 to 6 bases,
X2 is 0 or 1 nucleotide,
N1, N2 and N3 are each independently any nucleotide,
N4 and N7 is a pyrimidine or a modified pyrimidine,
N5 is a purine or a modified purine, and
N6 is a modified pyrimidine, A or a modified purine,
wherein at least two of the nucleotides N4, N5, N6 or N7 are modified purines or modified pyrimidines, and whereby the oligonucleotide comprises 20 nucleosides or less.

### Claim 3 (depends on 1)

The inhibitory oligonucleotide according to claim 1, wherein said oligonucleotide has the general formula (II):
N1CCTGGpypuGGGpxAGpy (II)
in which:
C is cytidine or a derivative thereof as defined in claim 1,
G is guanosine or a derivative thereof as defined in claim 1,
N1 is any nucleotide or no nucleotide,
py is a pyrimidine or a modified pyrimidine nucleotide,
pu is a purine or a modified purine nucleotide, and
px is a modified pyrimidine, A or a modified purine,
wherein at least two of the nucleotides py, pu and px are modified purines or modified pyrimidines selected from the group consisting of 7-deaza-desoxyguanosine, 7-deaza-2′-O-methylguanosine, inosine, diaminopurin, 6-thio-desoxyguanosine, 6-O-methyl-desoxyguanosine, 7-deaza-inosine, 7-deaza-7-iododesoxyguanosine, 7-aminopropargyldesoxaguanosine, 2-fluoro-cytosine, 5-methylcytosine.

### Claim 4 (depends on 3)

The inhibitory oligonucleotide according to claim 3, wherein said oligonucleotide has the general formula (III):
N1CCTGGpypuGGG (III)
in which C, G, N1, py, and pu have the meaning as defined in claim 3.

### Claim 5 (depends on 3)

The inhibitory oligonucleotide according to claim 3, wherein:
Py is 5-substituted cytidine selected from the group consisting of 5-methyl-dC, 5-bromo-dC and 5-octadienyl-dC, and
Pu is a 7-deaza purine derivative selected from the group consisting of 7-deaza-dG, 7-deaza-2′-O-methyl-G, inosine and 7-deaza-inosine and Px is dA or 5-iodo-dU.

### Claim 6 (depends on 1)

The inhibitory oligonucleotide according to claim 1, characterized in that said oligonucleotide has the sequence dC*dC*dT*dG*dG*dZ*mE*dG*dG*dG*dA*dA*dG*dT.

### Claim 7 (depends on 1)

The inhibitory oligonucleotide according to claim 1, characterized in that said oligonucleotide has the sequence dC*dC*dT*dG*dG*BC*dE*dG*dG*dG*JU*dA*dG*dT.

### Claim 8

An inhibitory oligonucleotide having the general formula (IV):
X1AATGGpypuGGGpxAGpy (IV)
wherein:
Py is 5-substituted cytidine selected from the group consisting of 5-methyl-dC, 5-bromo-dC and 5-octadienyl-dC,
Pu is a 7-deaza purine derivative selected from the group consisting of 7-deaza-dG, 7-deaza-2′-O-methyl-G, inosine and 7-deaza-inosine,
Px is dA, 5-substituted deoxyuridine, or 5-iodo-uridine, and
X1 is any nucleotide or no nucleotide.

### Claim 9 (depends on 1)

The inhibitory oligonucleotide according to claim 1, wherein said oligonucleotide comprises a TLR antagonist having strongly enhanced potency.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising at least one inhibitory oligonucleotide according to claim 1.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein said composition further comprises at least one additive and/or carrier.

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10, wherein said composition is formulated for the treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen in a subject in need thereof.
